Cardiff Oncology prices $40M underwritten offering of 15.4M shares at $2.60/sh

Cardiff Oncology, Inc.

Gross proceeds ~$40M from 15,384,619 shares at $2.60 per share, before underwriting discounts.
Net proceeds to fund onvansertib clinical costs for RAS-mutated metastatic colorectal cancer (mCRC).
New mutual fund and healthcare dedicated investors participated; existing investors also supported.
Expected close Dec 11, 2024; 90-day lock-up for directors and officers on share sales.
TD Cowen lead bookrunner; William Blair, H.C. Wainwright, Craig-Hallum also underwriters.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.